. Author manuscript; available in PMC: 2022 Jun 21.

Published in final edited form as: Endocrine. 2021 Jun 5;74(3):592–602. doi: 10.1007/s12020-021-02779-x

Table 2.

Event rates and hazards ratios (95% confidence interval) of study outcomes in propensity score-matched cohorts of new users of brand or generic levothyroxine

	Events per 1000 patient years^*		Hazard ratio (95% CI) brand vs. generic	P-value
Outcomes	Brand T4	Generic T4	Hazard ratio (95% CI) brand vs. generic	P-value

Atrial fibrillation	0.95	0.98	0.96 (0.58, 1.60)	0.88
Myocardial infarction	0.72	1.08	0.66 (0.39, 1.14)	0.14
Congestive heart failure	1.11	0.85	1.30 (0.78, 2.16)	0.31
Stroke	1.44	1.98	0.72 (0.49, 1.06)	0.10
Pneumonia	2.06	2.41	0.85 (0.61, 1.19)	0.34
Spine fractures	0.33	0.37	0.87 (0.38, 1.99)	0.73
Hip fractures	0.16	0.19	0.86 (0.26, 2.82)	0.81
Falls	0.07	0.06	1.02 (0.14, 7.32)	0.99

Censored on end of coverage, 30 days after end of treatment, event or brand to generic, generic to brand switch or switch to other thyroid medications